No known contraindications are listed in the manufacturer's labeling thus far. However, like many medications, prescribers should withhold dosing for any adverse drug reactions.

This drug requires permanent discontinuation in the event of:

- Any life-threatening bullous, blistering, or exfoliative skin lesions.

- Confirmed interstitial lung disease (ILD)

- Severe drug-induced hepatic impairment

- Persistent ulcerative keratitis

- Symptomatic left ventricle dysfunction

- Severe or intolerable adverse reaction occurring at a dose of 20 mg per day

This drug is not recommended during pregnancy, as no adequate clinical trials exist examining the drug's use during pregnancy. Instead, A strong recommendation is that women of reproductive age use an effective contraception method during therapy. It should be continued at least for two weeks after the last dose of afatinib. The manufacturer warns against using this medication during breastfeeding, given potential serious adverse reactions in a breastfed infant. Breastfeeding can resume two weeks after the last dose.